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Abstract
Introduction: In acromegalic patients, the prevalence of certain benign and malignant neoplasms is higher than that in the healthy popu-
lation. We retrospectively evaluated the prevalence of tumours in acromegalic patients treated at our department: the regional centre for
acromegalic patients for the Małopolskie voivodeship in Poland.
Material and methods: During the years 1983–2008, a hundred and one acromegalic patients (30 males and 71 women), of mean age 51.8 ±
± 15.4 years, were diagnosed and treated. Pituitary macroadenoma and microadenoma were stated in 63.4% and 25.7% of these patients,
respectively. In 10.9% of these patients no data on tumour diameter were available. The mean observation period was 9.4 ± 6.5 years. The
median levels of hGH and IGF-1 prior to neurosurgery were 20.2 (IQR = 34.9) ng/ml and 764.5 (IQR = 569.6) ng/ml, respectively.
Results: In the studied group of patients, we found the following prevalence of various tumours: nodular goitre — 64/101 patients (63.0%),
polyps of the colon — 13/101 patients (13.0%); uterine polyps — 4/101 patients (4.0%); and prostate adenoma — 2/101 patients (2.0%).
Among malignant tumours, thyroid cancer, endometrium and cervix cancer were the most frequent, each of these occurring in 3 patients
(3.0%). Colon cancer prevalence was 2.0% (in 2 patients).
Conclusions: From our retrospective study, we suggest an overall increase of tumour incidence in acromegalic patients. Prospective
multicentre studies are required to resolve the significance of this observation.
In our study group, the number of malignant neoplasms was significantly higher in patients with long-lasting uncontrolled disease (over
5 years), compared to patients with controlled disease. (Pol J Endocrinol 2010; 61 (1): 29–34)
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Streszczenie
Wstęp: Pacjentów z akromegalią charakteryzuje częstsze niż w zdrowej populacji występowanie nowotworów zarówno łagodnych, jak
i złośliwych. Autorzy ocenili retrospektywnie częstość występowania schorzeń nowotworowych u pacjentów z akromegalią leczonych
w Klinice Endokrynologii w Krakowie, małopolskim ośrodku regionalnym leczenia akromegalii.
Materiał i metody: W latach 1983–2008 diagnozowano i leczono 101 pacjentów z akromegalią (30 mężczyzn i 71 kobiet), średnia wieku
51,8 ± 15,4 lat. U 63,4% chorych stwierdzono obecność makrogruczolaka w przysadce, u 25,7% mikrogruczolaka, a u 10,9% chorych brak
danych określających wielkość guza. Mediana stężenia hGH i IGF-1 przed operacją wynosiła odpowiednio: 20,2 (IQR = 34,9) ng/ml
i 764,5 (IQR = 569,6) ng/ml.
Wyniki: W analizowanej grupie chorych stwierdzono występowanie: wola guzowatego — u 64/101 pacjentów (63%), polipy jelita grubego
— u 13/101 pacjentów (13%), polipy macicy — u 4/101 pacjentów (4%), gruczolaka prostaty — u 2/101 pacjentów (2%). Spośród nowotwo-
rów złośliwych najczęściej występowały: rak tarczycy, rak endometrium i szyjki macicy, każdy u 3 chorych (3%). Raka jelita grubego
stwierdzono u 2 pacjentów (2%).
Wnioski: Na podstawie przeprowadzonego badania retrospektywnego autorzy sugerują częstsze występowanie guzów nowotworo-
wych u pacjentów z akromegalią. Potrzebne są badania prospektywne większych liczebnie grup pacjentów, żeby określić znaczenie tych
obserwacji.
W badanej grupie pacjentów nowotwory złośliwe występowały znamiennie częściej u pacjentów z długotrwałą niekontrolowaną akro-
megalią (> 5 lat), w porównaniu z osobami, u których kontrolowano przebieg choroby. (Endokrynol Pol 2010; 61 (1): 29–34)
Słowa kluczowe: akromegalia, łagodne i złośliwe nowotwory, hGH i IGF-1
The study was performed as a statutory research of Collegium Medicum, Jagiellonian University: K/ZDS/000595
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Introduction
Acromegaly is a rare chronic disease caused by incre-
ased secretion of growth hormone (hGH). Over 99% of
cases of acromegaly result from the presence of pituita-
ry adenoma developed from somatotrope cells which
normally produce GH in the pituitary. The estimated
prevalence of acromegaly ranges between 50–70 cases/
/million.
A number of studies have confirmed increased mor-
bidity and mortality in acromegalic patients, related
mainly to cardiovascular, cerebrovascular, respiratory,
and metabolic disease complications [1]. Acromegalic
patients are also believed to show a risk higher than in
the general population of developing benign and mali-
gnant tumours mainly of the digestive tract (particular-
ly colorectal), brain, breast, or thyroid gland, as sugge-
sted by several multicenter studies [2, 3].
The aim of this preliminary study was to perform
a single-centre evaluation of the prevalence of benign
and malignant neoplasms in a group of acromegalic pa-
tients. The Department of Endocrinology at UJCM is
a regional centre for acromegalic patients for the Mało-
polskie voivodeship in Poland. Our acromegaly group
consisted of 101 patients in whom we determined the
number of tumours and their localization. We also as-
sessed the relationship between the presence of mali-
gnant tumours and serum levels of hGH and insulin-
like growth factor 1 (IGF-1) and the duration of con-
trolled and uncontrolled disease.
Material and methods
A group of 101 acromegalic patients (30 males, 71 wo-
men), mean age 51.8 ± 15.4 years, were diagnosed and
treated in our department during the years 1983–2008.
Pituitary macroadenoma and microadenoma were sta-
ted in 63.4% and 25.7% of these patients, respectively.
In 10.9% of these patients no data on tumour diameter
were available (Fig. 1). The mean observation period
was 9.4 ± 6.5 years. The mean period of uncontrolled
disease and the mean quiescent period were 6.4 ± 5.2
and 3.0 ± 5.5 years, respectively. The serum concentra-
tions of hGH and IGF-1 were measured using IRMA
(DiaSorin) and RIA (Biosource) methods, respectively.
In our analysis, we scored neoplasms only in patients
for whom acromegaly was stated as their primary dia-
gnosis. Our study was based on retrospective analysis
of patient histories.
For statistical analysis the basic statistics, Shapiro-
Wilk, U Mann-Whitney, Wilcoxon, and Fisher tests,
were used.
Results
In acromegalic male patients a higher frequency of
macroadenoma (84.6%) was observed, as compared to
female patients (67.7%). Different age-related frequen-
cies of acromegaly were observed in the groups of wo-
men and men. As shown in Figure 2, acromegaly was
most frequent in women aged between 50 and 59 years
(in their 6th decade) and in men aged between 40 and
49 years (in their 5th decade). The median levels of hGH
and IGF-1 prior to treatment were 20.2 (IQR = 34.9) ng/ml
and 764.5 (IQR = 569.6) ng/ml, respectively, as compa-
red to median levels of hGH and IGF-1 at the time of
completion of this study, for all patients in the group:
2.1 (IQR = 4,0) ng/ml and 304.3 (IQR = 397.3) ng/ml,
respectively (Fig. 3), the differences being statistically
significant (p < 0.05).
At the time of completion of this study, only the
median concentration of IGF-1 (Fig. 3) was significantly
higher in patients with active acromegaly 535.6 (IQR =
= 505.0) ng/ml, as compared to patients in whom the di-
sease was controlled, 172.9 (IQR = 115.7) ng/ml (p< 0.05).
The prevalence of various tumours in patients in the
studied group was as follows: nodular goitre — 63.0%
(64 patients), polyps of the colon — 13.0% (13 patients);
uterine myoma and polyps — 12% (12 patients) and
4.0% (4 patients), respectively, and prostate adenoma
— 2% (2 patients). Meningioma occurred in 3 (3.0%),
adrenal adenoma in 2 (2.0%) and parathyroid adeno-
ma in 1 (1.0%) of the patients studied. Among malignant
tumours, thyroid cancer, endometrium and cervix can-
cer were the most frequent, each of these occurring in
3 (3.0%) of the patients. Colon cancer occurred in 2  (2.0%)
Figure 1. Type of pituitary adenoma in acromegalic patients,
depending on their sex (%), n = 91. In 10 patients, no data on
tumour size were available
Rycina 1. Typ gruczolaka przysadki u pacjentów z akromegalią
w zależności od płci (%), n = 91. U 10 pacjentów brak danych
dotyczących wielkości gruczolaka
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of the patients. Single cases of breast, stomach, skin, and
small-cell lung cancer, were also observed (Table I). The
level of PSA was measured in all 30 men under obse-
rvation: the mean concentration was 1.3 ± 1.6 ng/ml.
Figure 4 represents the number of malignant and
benign neoplasms versus time of total duration of the
disease and time of uncontrolled acromegaly. The de-
pendence of the number of malignant neoplasms on
the duration of uncontrolled disease: less than 5 years
and over 5 years, was found to be statistically signifi-
cant (p £ 0.05, Fisher test). In our group of studied pa-
tients we found no dependence between the concen-
trations of hGH and IGF-1 and the frequency of occur-
rence of malignant neoplasms.
Discussion
Retrospective studies on mortality in acromegaly pa-
tients have shown some 24% of cancer-related deaths
in a group of over 5000 acromegalic patients [4]. This
has been recognized only recently, as improved mana-
gement of this disease has allowed acromegalic patients
to survive long enough to reach the age of increased
cancer risk. The aetiology of these tumours is unknown,
but it probably reflects increased levels of hGH and in-
sulin-like growth hormone (IGF-1) in the blood. Ano-
ther hypothesis is that due to possible genetic and epi-
genetic alterations, acromegaly is predisposed to incre-
ased cancer risk [4].
The prevalence/incidence of cancer in patients with
acromegaly remains controversial, as no increase in the
risk of cancer in acromegaly has been stated by some
authors [1, 5]. On the other hand, increased relative risk
(1.5–4-fold) for acromegalic patients to develop tumo-
urs, including colon, thyroid gland, prostate, brain, lung,
kidney, and skin cancers, and possibly haematological
malignancies, has also been reported [4]. In Sweden and
Figure 2. Frequency of acromegaly in patients in the female and
male age groups (%), n = 101
Rycina 2. Częstość występowania akromegalii u kobiet i mężczyzn
w zależności od wieku (%), n = 101
Figure 3. Median values of hGH and IGF-1 before treatment, and at completion of this study.  The differences between median levels of
hGH and IGF-1 prior to treatment and at completion of this work are statistically significant (p < 0.05)
Rycina 3. Wartości median stężenia hGH i IGF-1 przed leczeniem i na zakończenie niniejszej pracy. Różnice wartości mediany stężenia
hGH i IGF-1 przed leczeniem i na zakończenie niniejszej pracy są znamienne statystycznie (p < 0,05)
32
Prevalence of neoplasms in acromegaly Agata Bałdys-Waligórska et al.
PR
A
C
E 
O
R
Y
G
IN
A
LN
E
Denmark, an increased risk SIR (standardized incidence
ratio) of 1.5 for all cancers, except prostate, was found
in acromegaly, as compared to population values [2].
In our retrospectively analysed group of acromegaly
patients we observed 12 malignant tumours, which gives
a prevalence of 12% (12/101 patients), compared to the
crude incidence rate of 666 new cancer cases/100 000
inhabitants (0.67%) in the Małopolska region in 2006
[6]. Additionally, 108 benign tumours, mainly of the
thyroid, colon, and uterus, were found (Table I).
In acromegalic patients, the reported frequencies of
diffuse goitre and nodular goitre were 78-92% and 63%,
respectively [7, 8]. We also found nodular goitre by USG
in 64/101 (63%) of our patients, confirming these reports.
However, we did not observe any positive relationship
between GH/IGF-1 concentration and thyroid volume,
as found by Hermann et al. [8]. The prevalence of thy-
roid cancer in acromegaly is not known, as the popula-
tions of acromegalic patients studied are too small. In
retrospective studies, thyroid cancer constitutes 3.1%
of all malignancies in acromegaly. The evaluated relati-
ve risk for thyroid cancer was 2.5–4.3, but the number
of patients with thyroid cancer was very low: 1–3 pa-
tients [4]. Tita et al. [7] estimated the prevalence of thy-
roid cancer at 5.6% (7/125) in acromegalic patients, as
compared to 0.1% in the general population over iodi-
ne deficient areas. In an Italian multi-centre study,
a thyroid cancer prevalence of 1.2% (3/258 patients) was
found by Gasperi et al. [9].
In our material the prevalence of thyroid cancer was
3% (3/101 patients), in two of whom follicular cancers
and one papillary were stated. The cancer register at
the Centre of Oncology in Kraków [6] quotes the crude
incidence rate of thyroid cancer in the Małopolska re-
gion in 2006 at 10.8 for females and 2.2 for males per
100,000 inhabitants. We can therefore state an increase
in the prevalence of thyroid cancer in acromegaly; ho-
wever, the small size of our patient group does not ena-
ble standard epidemiological tools to be applied.
In vitro studies confirm the presence of IGF-1-R on
thyroid cancer cells and synthesis of IGF-1 by follicular
cells and papillary cell lines, while surgical thyroid spe-
cimens suggest local autocrine loop [4], thus suppor-
ting the hypothesis of the role of IGF-1 in the control of
thyroid follicular cell proliferation. Based on our expe-
rience, we believe that due to its high prevalence,
nodular goitre in acromegaly should be monitored
according to ATA guidelines, and FNAB (Fine Needle
Aspiration Biopsy) should be performed in nodules of
diameter ≥ 1 cm [10].
The issue of colon cancer risk in acromegaly is also
controversial [11]. As colon cancer may result from co-
lon polyp degeneration, the prevalence of colon polyps
in patients with acromegaly has been the subject of
Figure 4. Number of malignant and benign neoplasms versus
total duration of disease and duration of uncontrolled acromegaly.
The number of malignant neoplasms in the group of patients with
uncontrolled disease over 5 years is significantly higher than that
in the group of patients with uncontrolled disease less than 5 years
(Fisher test, p £ 0.05)
Rycina 4. Liczba nowotworów łagodnych i złośliwych w zależności
od całkowitego czasu trwania akromegalii i czasu trwania choroby
aktywnej. Liczba nowotworów złośliwych w grupie pacjentów
z aktywną akromegalią powyżej 5 lat jest znamiennie wyższa
w porównaniu do grupy pacjentów z aktywną chorobą trwajacą
poniżej 5 lat (test Fishera, p £ 0,05)
Table I. Number of malignant and benign neoplasms in
acromegalic patients, n = 101
Tabela I. Liczba złośliwych i łagodnych nowotworów
u pacjentów z akromegalią, n = 101
Localization Malignant Benign Total
neoplasm neoplasm
Thyroid gland 3 64 67
Colon 2 13 15
Stomach 1 1 2
Lung 1 – 1
Skin 1 1 2
Uterus 3 16 19
Breast 1 – 1
Liver – 3 3
Nasopharynx – 1 1
Meningioma – 3 3
Adrenal glands – 2 2
Parathyroid glands – 1 1
Prostate – 2 2
Bone – 1 1
Total 12 108 120
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many studies. A 22–26% prevalence of colon adenoma
was demonstrated in a prospective study at Bartholo-
mew’s Hospital, UK [12] and by a multicenter study in
Italy [13]. In our group of patients, we found the pre-
valence of colon polyps to be 13% (13/101). Prospective
studies show that up to 45% of these patients have
colonic polyps, which are adenomatous in 24% of cases
[14]. The correlation between hGH and IGF-1 concen-
trations and the incidence of colonic polyps has not
been clearly elucidated. In our study group, we also
found no relationship between hGH and IGF-1 con-
centration and the frequency of occurrence of mali-
gnant neoplasms.
The prevalence of colon carcinoma in acromegaly
was evaluated at 4–5% [12, 13]. We observed only two
cases of colon cancer (2%) which might be a biased va-
lue due to the small group of our patients. For compari-
son, the crude incidence rate of colorectal cancer in the
Małopolska region in 2006 was estimated at 40.0 for males
and 30.6 for females per 100,000 inhabitants [6]. Based
on three population studies in acromegalic series, Re-
nehan [15] calculated the risk ratio for colorectal cancer
to be 2.04. Until recently, total colonoscopy was advi-
sed for newly diagnosed patients [4] and then accor-
ding to American Cancer Society guidelines [16] for
patients with increased risk, every 5 years if no cancer
or polyps were detected. This statement is currently un-
der revision as, based on a population study and the
definition of the high-risk group of colorectal cancer, acro-
megalic patients are just above the average-risk value.
Therefore, Renehan recommends screening colonosco-
py after the 50th birthday of acromegalic patients (15).
A 4-fold higher risk of breast cancer in acromegalic
patients stated by Nabarro [17] has not been confirmed
by other authors. In our group of 101 patients, we fo-
und only one case of breast cancer.
Acromegaly is associated with prostate hyperplasia
and macro- and microcalcifications, but the incidence
of cancer does not appear to be elevated significantly
[18]. In our study group, the PSA level was measured
in all 30 men under observation, their mean PSA con-
centration falling within normal range. Prostate adeno-
ma, but no cancer, was stated in 2 patients.
Ron, Orme and Barris [1–3] did not confirm any in-
creased prevalence of lung cancer in acromegalic pa-
tients, although SCLC (small cell lung cancer) and non
SCLC express IGF-1R (IGF-1 receptor) and produce IGF-1,
and stimulation with exogenous IGF-1 induces prolife-
ration of small cell lung cancer cell lines [19, 20]. In our
group of patients, one case of SCLC (1%) was found, as
compared with the crude incidence rate of all lung can-
cer of 80.8 for males and 22.0 for females per 100,000
inhabitants of the Małopolska region in 2006 [6].
We found that the dependence of the number of
malignant neoplasms on the duration of uncontrolled
disease, less than 5 years and over 5 years, was statisti-
cally significant. The difference in the number of mali-
gnant neoplasms versus total duration of acromegaly
(less than 10 years and over 10 years) was not signifi-
cant. In a nationwide survey for cancer incidence in
acromegaly in Finland [21], three cases of colorectal can-
cer v. 0.7 expected were found after 5 years of observa-
tion in the group of patients with post-treatment hGH
concentration ≥ 2.5 ng/ml. This proves the importance
of efficient treatment of acromegaly not only to reduce
mortality but also to reduce the risk of cancer occurren-
ce. Acromegaly is a rare disease indeed, making it diffi-
cult for individual centres to gather sufficient numbers
of patients for statistical analysis. Therefore, due to the
small population of our study group (101 patients) and
the small numbers of cases of malignant neoplasms
found [7], we report our results in terms of prevalence
within our group, rather than as standardized inciden-
ce rates, SIR. Meta-analyses and multicentre studies
have to be undertaken to estimate the risk of cancer in
acromegaly patients.
Conclusions
Based on our retrospective study, we suggest an ove-
rall increase of tumour incidence in acromegalic pa-
tients. Prospective studies are required to resolve the
significance of this observation.
In our group of patients, we found the number of
malignant neoplasms to be significantly higher in pa-
tients with long-lasting uncontrolled disease (over
5 years). We found no statistically significant difference
in the number of malignant neoplasms versus total du-
ration of acromegaly (less than 10 years and over
10 years).
We propose that, due to the high incidence of no-
dular goitre, acromegalic patients should be monitored
according to ATA guidelines. In particular, fine-needle
aspiration biopsy of nodules of size greater than 1 cm
should be performed.
We consider that regular screening of acromegalic
patients for polyps and colon cancer after their 50th bir-
thday, and for prostate cancer (PSA, rectal examination
or USG), is advisable.
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